Just came across UBT251 and somehow haven't seen much talk about it.
Basically another triple agonist like reta - GLP-1 + GIP + glucagon.
What caught my attention is the Phase 2 result. Up to 19.7% average weight loss in 24 weeks. That's kinda crazy considering it was only 6 months and the weight loss didn't seem to be done yet.
Novo picked up the rights outside China and they're developing it globally now.
What I'm trying to understand is what actually makes this different from reta if they're hitting the same 3 receptors. Different receptor balance/potency maybe?
Could this realistically end up better than reta or are we just looking at basically another version of the same thing?
Anyone been following UBT251 more closely?